Pain, Placebo, and Test of Treatment Efficacy: a Narrative Review

Overview

Journal Br J Anaesth

Publisher Elsevier

Specialty Anesthesiology

Date 2019 Mar 28

PMID 30915982

Citations 45

Authors

Lene Vase

Karolina Wartolowska

Affiliations

Soon will be listed here.

Abstract

Over the past decade, the mechanisms underlying placebo effects have begun to be identified. At the same time, the placebo response appears to have increased in pharmacological trials and marked placebo effects are found in neurostimulation and surgical trials, thereby posing the question whether non-pharmacological interventions should be placebo-controlled to a greater extent. In this narrative review we discuss how the knowledge of placebo mechanisms may help to improve placebo control in pharmacological and non-pharmacological trials. We review the psychological, neurobiological, and genetic mechanisms underlying placebo analgesia and outline the current problems and potential solutions to the challenges with placebo control in trials on pharmacological, neurostimulation, and surgical interventions. We particularly focus on how patients' perception of the therapeutic intervention, and their expectations towards treatment efficacy may help develop more precise placebo controls and blinding procedures and account for the contribution of placebo factors to the efficacy of active treatments. Finally, we discuss how systematic investigations into placebo mechanisms across various pain conditions and types of treatment are needed in order to 'personalise' the placebo control to the specific pathophysiology and interventions, which may ultimately lead to identification of more effective treatment for pain patients. In conclusion this review shows that it is important to understand how patients' perception and expectations influence the efficacy of active and placebo treatments in order to improve the test of new treatments. Importantly, this applies not only to assessment of drug efficacy but also to non-pharmacological trials on surgeries and stimulation procedures.

Citing Articles

Advancing the prediction and understanding of placebo responses in chronic back pain using large language models.

Nunes D, Furrer D, Berger S, Cecchi G, Ferreira-Gomes J, Neto F medRxiv. 2025; .

PMID: 39974011 PMC: 11838926. DOI: 10.1101/2025.01.21.25320888.

The efficiency of single-session photobiomodulation on healing of periapical bone lesions using CBCT: a randomized clinical trial.

Hamdy Ismail H, Obeid M, ElSaid Hassanein E Lasers Med Sci. 2025; 40(1):31.

PMID: 39847087 PMC: 11757862. DOI: 10.1007/s10103-024-04242-5.

The Two Sides of Placebo Analgesia: Differential Functional Connectivity Reveals Mechanisms of Placebo Analgesic Response.

Bush N, Cushnie A, Boissoneault J, Aghabeigi S, Alexander C, Staud R J Pain Res. 2025; 18():189-201.

PMID: 39816204 PMC: 11733195. DOI: 10.2147/JPR.S483157.

Clinical predictors of treatment response to gabapentin in women with unexplained chronic pelvic pain.

Coxon L, Amer M, Daniels J, Doust A, Mackenzie S, Horne A Front Pharmacol. 2024; 15:1460206.

PMID: 39691398 PMC: 11649436. DOI: 10.3389/fphar.2024.1460206.

E-52862-A selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy.

Galvez R, Mayoral V, Cebrecos J, Medel F, Morte A, Sust M Eur J Pain. 2024; 29(1).

PMID: 39629978 PMC: 11616472. DOI: 10.1002/ejp.4755.

References

Dworkin R, Turk D, Peirce-Sandner S, Baron R, Bellamy N, Burke L . Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010; 149(2):177-193. DOI: 10.1016/j.pain.2010.02.018. View

Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F . Response expectancies in placebo analgesia and their clinical relevance. Pain. 2001; 93(1):77-84. DOI: 10.1016/S0304-3959(01)00296-2. View

Gelijns A, Ascheim D, Parides M, Kent K, Moskowitz A . Randomized trials in surgery. Surgery. 2009; 145(6):581-7. PMC: 2935803. DOI: 10.1016/j.surg.2009.04.003. View

Price D, Finniss D, Benedetti F . A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2007; 59:565-90. DOI: 10.1146/annurev.psych.59.113006.095941. View

Vase L, Riley 3rd J, Price D . A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain. 2002; 99(3):443-452. DOI: 10.1016/S0304-3959(02)00205-1. View

Vase L, Robinson M, Verne N, Price D . Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain. 2005; 115(3):338-347. DOI: 10.1016/j.pain.2005.03.014. View

Hrobjartsson A, Forfang E, Haahr M, Als-Nielsen B, Brorson S . Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol. 2007; 36(3):654-63. DOI: 10.1093/ije/dym020. View

Flaten M . Pain-related negative emotions and placebo analgesia. Handb Exp Pharmacol. 2014; 225:81-96. DOI: 10.1007/978-3-662-44519-8_5. View

Tuttle A, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett G . Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015; 156(12):2616-2626. DOI: 10.1097/j.pain.0000000000000333. View

10.

Hall K, Loscalzo J, Kaptchuk T . Genetics and the placebo effect: the placebome. Trends Mol Med. 2015; 21(5):285-94. PMC: 4573548. DOI: 10.1016/j.molmed.2015.02.009. View

11.

Scott D, Stohler C, Egnatuk C, Wang H, Koeppe R, Zubieta J . Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008; 65(2):220-31. DOI: 10.1001/archgenpsychiatry.2007.34. View

12.

Hull S, Colloca L, Avins A, Gordon N, Somkin C, Kaptchuk T . Patients' attitudes about the use of placebo treatments: telephone survey. BMJ. 2013; 347:f3757. PMC: 3698941. DOI: 10.1136/bmj.f3757. View

13.

Wartolowska K, Gerry S, Feakins B, Collins G, Cook J, Judge A . A meta-analysis of temporal changes of response in the placebo arm of surgical randomized controlled trials: an update. Trials. 2017; 18(1):323. PMC: 5508709. DOI: 10.1186/s13063-017-2070-9. View

14.

Geers A, Kosbab K, Helfer S, Weiland P, Wellman J . Further evidence for individual differences in placebo responding: an interactionist perspective. J Psychosom Res. 2007; 62(5):563-70. DOI: 10.1016/j.jpsychores.2006.12.005. View

15.

Schulz K, Altman D, Moher D . [CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (Chinese version)]. Zhong Xi Yi Jie He Xue Bao. 2010; 8(7):604-12. DOI: 10.3736/jcim20100702. View

16.

Petersen G, Finnerup N, Norskov K, Grosen K, Pilegaard H, Benedetti F . Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain. 2012; 153(6):1292-1300. DOI: 10.1016/j.pain.2012.03.011. View

17.

Vase L, Petersen G, Riley 3rd J, Price D . Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain. 2009; 145(1-2):36-44. DOI: 10.1016/j.pain.2009.04.008. View

18.

Rabkin J, Markowitz J, Stewart J, McGrath P, Harrison W, Quitkin F . How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res. 1986; 19(1):75-86. DOI: 10.1016/0165-1781(86)90094-6. View

19.

Kam-Hansen S, Jakubowski M, Kelley J, Kirsch I, Hoaglin D, Kaptchuk T . Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014; 6(218):218ra5. PMC: 4005597. DOI: 10.1126/scitranslmed.3006175. View

20.

Simpson D, Rice A, Emir B, Landen J, Semel D, Chew M . A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain. 2014; 155(10):1943-54. DOI: 10.1016/j.pain.2014.05.027. View